Top Takeaways:

• Mandatory use of new forms begins July 6, 2025: All PMTA and SE submissions must use the updated FDA forms—or face refusal to accept.
• Six key forms revised or introduced: Three PMTA forms (4057, 4057a, 4057b) and three SE forms (3965, 3965a, new 3965b), reflecting public comments and aiming to boost clarity and data quality.
• New validator tool launched: FDA released Product Form Validator Tool 2.0 for PMTA 4057b and SE 3965b to help verify form accuracy pre-submission .

The FDA last week announced it will now require the immediate use of six revised or newly introduced forms for applications under both the premarket tobacco product application (PMTA) and substantial equivalence (SE) pathways. Beginning July 6, 2025, all submissions must use these updated forms; failure to do so may result in outright refusal .

The move is part of the agency’s efforts to enhance transparency, efficiency, and regulatory consistency in overseeing new tobacco products, according to a release. The updated forms incorporate guidance from public comments to streamline application requirements.

PMTA forms:

• Form FDA 4057 – PMTA Submission
• Form FDA 4057a – PMTA Amendment & Correspondence
• Form FDA 4057b – PMTA “Unique Identifying Information” (formerly grouping spreadsheet

SE report forms:

• Form FDA 3965 – SE Report Submission
• Form FDA 3965a – SE Amendment & Correspondence (replaces 3964)
• Form FDA 3965b – SE “Unique Identifying Information” (new)

The revisions include expanded instructions and additional data fields to ensure applicants provide clearer and more complete submissions .

To support accurate submissions, the FDA also launched Product Form Validator Tool 2.0, which allows pre-submission data validation for Forms 4057b and 3965b. The tool flags inconsistencies and helps applicants ensure compliance.

Compliance is no longer optional. Under its “Refuse to Accept” policy, FDA will likely reject applications that fail to use the updated forms or omit required information .

The new rule impacts both next-generation products like vaping devices and novel nicotine products, as the forms play a key role in the FDA’s evaluation of a product’s appropriateness for public health.

What Stakeholders Should Do

• Update internal submission procedures to incorporate the six new forms by July 6.
• Train regulatory and legal teams on revised form requirements and common errors (e.g., missing fields, misformatted spreadsheets).
• Use the FDA Validator Tool 2.0 to pre-check form 4057b and 3965b submissions for format consistency.
• Monitor guidance and agency support channels, especially for amendments and resubmissions of PMTA/SE applications.
• Engage with FDA early on, requesting Regulatory Health Project Manager contacts or industry account managers to clarify transition protocols.

FDA’s July 6 deadline underscores the agency’s intent to modernize the PMTA and SE review processes—while also raising the operational bar for companies. For smaller players already navigating PMTA complexity, this shift elevates the stakes.